key: cord-0974931-eelpdj5j authors: Aragão, Luiz Guilherme H. S.; Oliveira, Júlia T.; Temerozo, Jairo R.; Mendes, Mayara A.; Salerno, José Alexandre; Pedrosa, Carolina da S. G.; Puig-Pijuan, Teresa; Veríssimo, Carla P.; Ornelas, Isis M.; Torquato, Thayana; Vitória, Gabriela; Sacramento, Carolina Q.; Fintelman-Rodrigues, Natalia; Dias, Suelen da Silva Gomes; Soares, Vinicius Cardoso; Souza, Leticia R. Q.; Karmirian, Karina; Goto-Silva, Livia; Biagi, Diogo; Cruvinel, Estela M.; Dariolli, Rafael; Furtado, Daniel R.; Bozza, Patrícia T.; Borges, Helena L.; Souza, Thiago Moreno L.; Guimarães, Marília Zaluar P.; Rehen, Stevens title: WIN 55,212-2 shows anti-inflammatory and survival properties in human iPSC-derived cardiomyocytes infected with SARS-CoV-2 date: 2021-09-17 journal: bioRxiv DOI: 10.1101/2021.02.20.431855 sha: fec5b23fb2525f40ef6fbfaeaf427ffde611e681 doc_id: 974931 cord_uid: eelpdj5j Coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which can infect several organs, especially impacting respiratory capacity. Among the extrapulmonary manifestations of COVID-19 is myocardial injury, which is associated with a high risk of mortality. Myocardial injury, caused directly or indirectly by SARS-CoV-2 infection, can be triggered by inflammatory processes that cause damage to the heart tissue. Since one of the hallmarks of severe COVID-19 is the “cytokine storm”, strategies to control inflammation caused by SARS-CoV-2 infection have been considered. Cannabinoids are known to have anti-inflammatory properties by negatively modulating the release of pro-inflammatory cytokines. Herein, we investigated the effects of the cannabinoid agonist WIN 55,212-2 (WIN) in human iPSC-derived cardiomyocytes (hiPSC-CMs) infected with SARS-CoV-2. WIN did not modify angiotensin-converting enzyme II protein levels, nor reduced viral infection and replication in hiPSC-CMs. On the other hand, WIN reduced the levels of interleukins 6, 8, 18 and tumor necrosis factor-alpha (TNF-α) released by infected cells, and attenuated cytotoxic damage measured by the release of lactate dehydrogenase (LDH). Our findings suggest that cannabinoids should be further explored as a complementary therapeutic tool for reducing inflammation in COVID-19 patients. Technologies) for 1 hour. Nuclei were stained with 300 nM 4ʹ-6-diamino-2-259 phenylindole (DAPI) for 5 minutes and each well was mounted with two drops of 50% 260 PBS-Glycerol. Images (at least 10 fields per well) of hiPSC-CMs were acquired using 261 Operetta® High-Content Imaging System (Perkin Elmer) with a 20x long working 262 distance (WD) objective lens. A Leica TCS-SP8 confocal microscope was used to 263 acquire images of hiPSC-CMs immunostained for TNNT2 and F-actin with the 63x 264 objective (Fig S3) . 265 Neutral red uptake cell viability assay 266 Briefly, hiPSC-CMs were seeded in 96-well plates. After reaching 80-90% confluency, 267 cells were exposed to concentrations of WIN ranging between 10 nM-10 μM for 72 268 hours. Next, the medium was replaced, cells were washed with PBS 1x and 200 μL of 269 neutral red dye diluted in the hiPSC-CMs medium was added to each well at a final 270 Blotting System (# GERPN2232, Sigma) for 5 minutes, and chemiluminescence was 295 13 detected with an Odyssey-FC Imaging System ® (LI-COR Biosciences, EUA). After 296 CB1 or CB2 detection a stripping protocol was used on the membranes for further 297 detection of actin. Membranes were incubated with a stripping buffer (pH 2.2, 200 mM 298 glycine, 0.1% SDS, and 1% Tween-20) for three cycles of 10 minutes. Next, the buffer 299 was discarded, and the membranes were washed three times with PBS and three 300 times for 5 minutes with 0.1% TBS-T. Then, membranes were blocked again and 301 proceeded with the above-described steps. 302 Statistical analyses were performed using GraphPadPrism software version 8.0 304 (GraphPad, EUA). Results were expressed as the mean and standard error of the 305 mean (SEM). For comparisons between two experimental groups, unpaired two-tailed 306 Student's t-test or Mann-Whitney U test was used, whereas two-way analysis of 307 variance (ANOVA) or Kruskal-Wallis test followed by Tukey's test was used for 308 comparisons between three or more groups. A p-value smaller than 0.05 was 309 accepted as statistically significant. whereas ACE2 protein levels in WIN treated cells was 1.16 ± 0.39, normalized to 345 control ( Fig 1A, B and C, and Fig S2) . 346 Next, we asked whether WIN could reduce hiPSC-CMs SARS-CoV-2 infection by 348 mechanisms other than ACE2 modulation. For this, cells were pretreated with 1 µM 349 CoV-2; 26±12%) (Fig 2A and B) . 359 Since viral infection and replication are correlated but orchestrated by different 360 mechanisms, we asked whether WIN could decrease SARS-CoV-2 replication in 361 hiPSC-CMs. We observed that despite a decrease in average viral titer when 362 comparing SARS-CoV-2 WIN (6.99 × 10 5 ± 4.39 × 10 5 PFU/mL) with SARS-CoV-2 363 (2.18 × 10 6 ± 9.96 × 10 5 PFU/mL), the difference was not statistically significant (Fig 364 2C) . 365 The "cytokine storm" is a hallmark of severe COVID-19 cases and cannabinoids have 368 well-known anti-inflammatory properties. We asked whether WIN could reduce the 369 release of the inflammatory cytokines IL-6, IL-8, TNF-α by hiPSC-CMs in vitro. Cells It has been previously reported that SARS-CoV-2 infection causes apoptosis in without WIN, the release of LDH increased 463% and 174%, respectively, in hiPSC-388 had significantly lower increments of 72% and 40%, respectively ( Figure 3D) . 390 Cannabinoids have been proposed as potential treatment and prevention of COVID-392 19, due to their antiviral, cytoprotective and anti-inflammatory properties (Marchalant, This study showed that pretreatment with a cannabinoid receptor agonist reduced 476 cytotoxicity and proinflammatory cytokines released by human cardiomyocytes 477 infected with SARS-CoV-2. These results suggest that the therapeutic potential of 478 cannabinoids in protecting the heart against SARS-CoV-2 infection should be further 479 explored, in particular regarding selective action on the CB1 receptor. Agonist of Cannabinoid Receptors Amyloid β1-42 Effects on Astrocytes in Primary Culture Anti-inflammatory property of the cannabinoid agonist 597 WIN-55212-2 in a rodent model of chronic brain inflammation Vijayanand 601 P. 2020. Imbalance of Regulatory and Cytotoxic SARS-CoV-2-Reactive CD4+ T Cells in 602 COVID-19 Endocannabinoid/Lysophosphatidylinositol Receptors Marks the Severity of Alzheimer's 606 Disease in a Preclinical Model: A Therapeutic Opportunity Cannabinoids as therapeutic agents in 609 cardiovascular disease: a tale of passions and illusions Angiotensin II-Induced Cardiac Effects Are Modulated 613 by Endocannabinoid-Mediated CB1 Receptor Activation CB1 cannabinoid receptors promote oxidative stress and 617 cell death in murine models of doxorubicin-induced cardiomyopathy and in human 618 cardiomyocytes Molecular characterization of a peripheral receptor 620 for cannabinoids Cardiovascular effects of 627 marijuana and synthetic cannabinoids: the good, the bad, and the ugly SARS-CoV-2 infection of human 632 iPSC-derived cardiac cells reflects cytopathic features in hearts of patients with COVID-633 19 Huber 637 TB. 2020. Multiorgan and Renal Tropism of SARS-CoV-2 Proliferator-Activated Receptor-α Inhibition Protects Against Doxorubicin-Induced 641 Attenuation of HIV-1 replication in macrophages by cannabinoid receptor 2 645 agonists Cannabinoids and Viral Infections Cannabinoid Receptor Type 2: 649 A Possible Target in SARS-CoV-2 (CoV-19) Infection? In vitro determination of the efficacy of illicit synthetic cannabinoids at 653 CB1 receptors The interaction between the endocannabinoid system and 656 the renin angiotensin system and its potential implication for COVID-19 infection SARS-CoV-2 infection in human cardiomyocytes by targeting the Sigma-1 receptor 663 disrupts cytoskeleton architecture and contractility Human iPSC-Derived Cardiomyocytes Are Susceptible to SARS-CoV-2 Infection Delta-669 9-tetrahydrocannabinol protects cardiac cells from hypoxia via CB2 receptor activation 670 and nitric oxide production Cardiomyocyte Hypertrophy and Attenuated by Peroxisome Proliferator-activated 675 Effects of cannabinoid receptor agonist and 678 antagonist ligands on production of inflammatory cytokines and anti-inflammatory 679 28 interleukin-10 in endotoxemic mice Cannabinoid CB 2 receptor 686 ligand profiling reveals biased signalling and off-target activity Effects of 689 cannabinoids and their receptors on viral infections SARS-CoV-2 receptor ACE2 expression in the human heart: cause of a post-692 pandemic wave of heart failure? Cardiac inflammation 695 in COVID-19: Lessons from heart failure Endothelial cell infection and endotheliitis 699 in COVID-19 In search of preventive strategies: novel high-CBD Cannabis sativa extracts modulate 702 ACE2 expression in COVID-19 gateway tissues Hypoxia-stimulated cardiac fibroblast production of IL-6 promotes myocardial fibrosis via the TGF-β 1 signaling pathway Drug-induced cardiomyopathies Cell-Derived Cardiomyocytes Platform to Study SARS-CoV-2 Related Myocardial Injury Hypoxic 716 stress induces cardiac myocyte-derived interleukin-6 Structural basis for the recognition of 719 SARS-CoV-2 by full-length human ACE2 COVID-19 and the cardiovascular system Angiotensin-converting enzyme 2 suppresses pathological 725 hypertrophy, myocardial fibrosis, and cardiac dysfunction The clinical characteristics of myocardial injury in severe 728 and very severe patients with 2019 novel coronavirus disease Figure 1. WIN does not modulate ACE2 in hiPSC-CMs. (A) Relative mRNA expression levels 734 of ACE2 in WIN-treated hiPSC-CMs expressed as fold change relative to untreated condition Quantification of western blots by densitometry normalized by actin expression. ACE2 736 mRNA and protein levels were comparable between WIN-treated and untreated hiPSC-CMs Error bars represent standard errors of the means (SEMs) from three (A) and four (B) Figure 2. WIN does not reduce SARS-CoV-2 infection and replication in hiPSC-CMs Representative micrographs of MOCK and SARS-CoV-2-infected hiPSC-CM pre-treated or 748 not with 1 μM WIN for 24 hours. hiPSC-CM were immunostained with SARS-CoV-2 749 convalescent serum (CS) (red) and counterstained with DAPI (blue) at 48h post-infection CS immunoreactivity was comparable 751 between treated and untreated hiPSC-CM. (C) Viral titer quantification by plaque forming units 752 assay using the supernatants of the SARS-CoV-2 infected hiPSC-CMs. Viral titer was 753 comparable between treated and untreated hiPSC-CM. Error bars represent standard errors 754 of the means (SEM) from three TNF-α (C), and (D) release of lactate dehydrogenase (LDH) from MOCK treated or not with 1 μM WIN for 24 hours, were analyzed 760 at 24-, 48-and 72-hours post-infection (h.p.i.). Cytokine levels were higher in SARS-CoV-2 761 compared with control (MOCK), and lower in SARS-CoV-2 WIN when LDH release-absorbance levels relative to MOCK was higher in SARS-CoV-2 763 compared with SARS-CoV-2 WIN. Data represent means and standard errors of the means 764 (SEM) from three independent experiments from one cell line CB1 and CB2 receptors expression. (A) The figure shows agarose gel of end-point 772 PCR products for cDNA from hiPSC-CMs. One single specific band was detected for CB1 773 receptor (125bp), while no such band was detected for CB2 receptor bp) was used as an endogenous control to confirm efficiency of the amplification reaction and 775 quality of cDNA template. Data from two independent experiments. (B) Western blot detection 776 of CB1 receptor protein levels in hiPSC-CMs. The arrows indicate the specific bands, 777 corresponding to the molecular weight predicted to CB1 receptor